Analyst IMS Investment Management Services Ltd. cut its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 48.6% in the first quarter, reports Holdings Channel.com. The company held 1,900 shares of the company after selling 1,800 shares during the period. The holdings of analyst IMS Investment Management Services Ltd. in Johnson & Johnson were worth $337,000 at the end of the last quarter.
Other institutional investors have also recently changed their positions in the company. Riversedge Advisors LLC increased its stake in Johnson & Johnson by 8.6% during the 4th quarter. Riversedge Advisors LLC now owns 3,664 shares of the company valued at $627,000 after buying 289 additional shares in the last quarter. Bard Financial Services Inc. increased its stake in Johnson & Johnson by 0.8% in the fourth quarter. Bard Financial Services Inc. now owns 119,887 shares of the company worth $20,509,000 after purchasing an additional 957 shares in the last quarter. Lake Street Financial LLC increased its stake in Johnson & Johnson by 23.7% in the fourth quarter. Lake Street Financial LLC now owns 27,467 shares of the company worth $4,699,000 after purchasing an additional 5,257 shares in the last quarter. DDD Partners LLC increased its stake in Johnson & Johnson by 1.6% in the 4th quarter. DDD Partners LLC now owns 107,920 shares of the company worth $18,462,000 after purchasing an additional 1,666 shares last quarter. Finally, Corepath Wealth Partners LLC increased its stake in Johnson & Johnson by 3.9% in the 4th quarter. Corepath Wealth Partners LLC now owns 1,899 shares of the company worth $329,000 after buying 72 additional shares in the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s shares.
Separately, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a transaction dated Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the SEC, accessible via this hyperlink. In other news, Executive Vice President Kathryn E. Wengel sold 40,000 shares in a trade that took place on Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. As a result of the transaction, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, CAO Robert J. Decker sold 8,462 shares in a trade that took place on Thursday, May 26. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following completion of the transaction, the chief accounting officer now owns 15,473 shares of the company, valued at approximately $2,785,140. The disclosure of this sale can be found here. Insiders own 0.35% of the shares of the company.
Johnson & Johnson Stock Performance
Shares of JNJ opened at $170.71 on Thursday. Johnson & Johnson has a one-year low of $155.72 and a one-year high of $186.69. The company’s 50-day moving average is $176.48 and its 200-day moving average is $174.34. The company has a market cap of $449.21 billion, a price-to-earnings ratio of 23.01, a growth price-to-earnings ratio of 3.41, and a beta of 0.63. The company has a debt ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39.
Johnson & Johnson (NYSE:JNJ – Get Rating) last reported quarterly results on Tuesday, July 19. The company reported earnings per share (EPS) of $2.59 for the quarter, beating analyst consensus estimates of $2.57 by $0.02. The company posted revenue of $24.02 billion for the quarter, versus a consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company’s quarterly revenue increased 3.0% from the same quarter last year. During the same quarter last year, the company posted EPS of $2.48. Sell-side analysts expect Johnson & Johnson to post 10.2 EPS for the current fiscal year.
Johnson & Johnson announces dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13 per share. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.65%. The ex-date of this dividend is Monday, August 22. Johnson & Johnson’s payout ratio is currently 60.92%.
A Wall Street analyst gives his opinion
Several brokerages have commented on JNJ. StockNews.com upgraded Johnson & Johnson shares from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 report. Citigroup cut its price target on Johnson & Johnson shares from $205.00 to $201.00 in a research report Wednesday. Daiwa Capital Markets assumed coverage for Johnson & Johnson shares in a Wednesday, June 22 research report. They issued an “outperformance” rating on the stock. Credit Suisse Group raised its price target on Johnson & Johnson shares from $200.00 to $205.00 and gave the stock an “outperform” rating in a Wednesday, April 20 research report. Finally, Wells Fargo & Company raised its price target on Johnson & Johnson stock from $190.00 to $195.00 and gave the stock an “overweight” rating in a Wednesday, July 13 research report. . Four research analysts gave the stock a hold rating, six gave the company a buy rating and one gave the company a strong buy rating. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $191.13.
About Johnson & Johnson
(Get a rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds hold JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get Rating).
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.